Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Apr 2023
Adding mint flavor to e-cigarette liquids increases the amount of vapour particles produced and is linked, according to a recent study published in Respiratory Research.
Read Full NewsOlder adults with chronic disease who have less education, lower income, and no active jobs tend to experience symptoms of depression.
A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.
A national cohort study compares the safety and efficacy of weight-based and fixed-dose pembrolizumab regimens in patients with advanced non-small cell lung cancer.
Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.
1.
According to the Lancet, proton beam therapy may shorten the course of treatment for patients with breast cancer.
2.
Annual whole-body, low-dose CT aids management of smoldering multiple myeloma
3.
Sydney researchers identify new tools to improve cancer diagnosis and treatment.
4.
Coffee, Tea Tied to Lower Risk of Head and Neck Cancer
5.
How wildfires pose challenges to cancer care
1.
An Introduction To The CA 15-3 Tumor Marker Test For Cancer Patients
2.
TAR-200 in Bladder Cancer: Precision Drug Delivery Driving Oncology Advances
3.
Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia
4.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
5.
Understanding the Importance of CA125: A Comprehensive Guide
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
3.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
4.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
5.
Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge